ISPOR - PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

Full Text

PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

Abstract

Authors

C Renaudin W Berger D Liens WJ Valentine AJ Palmer S Roze

Back to Volume 9, Issue 6

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now